Candel Therapeutics (CADL) Cash from Investing Activities (2020 - 2025)

Candel Therapeutics' Cash from Investing Activities history spans 4 years, with the latest figure at -$27000.0 for Q4 2023.

  • On a quarterly basis, Cash from Investing Activities rose 90.22% to -$27000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$280000.0, a 78.41% increase, with the full-year FY2025 number at -$560000.0, down 3400.0% from a year prior.
  • Cash from Investing Activities hit -$27000.0 in Q4 2023 for Candel Therapeutics, up from -$103000.0 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for CADL hit a ceiling of $20.2 million in Q4 2020 and a floor of -$732000.0 in Q3 2020.
  • Historically, Cash from Investing Activities has averaged $1.1 million across 4 years, with a median of -$222000.0 in 2021.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 102.5% in 2021 and later soared 111.11% in 2023.
  • Tracing CADL's Cash from Investing Activities over 4 years: stood at $20.2 million in 2020, then plummeted by 102.5% to -$504000.0 in 2021, then skyrocketed by 45.24% to -$276000.0 in 2022, then surged by 90.22% to -$27000.0 in 2023.
  • Business Quant data shows Cash from Investing Activities for CADL at -$27000.0 in Q4 2023, -$103000.0 in Q3 2023, and -$169000.0 in Q2 2023.